redefine 2 - Search News

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Fox Business on MSN · 4d

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Endocrinology Advisor · 3d

Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Healio4d

CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Devdiscourse4d

Novo Nordisk's CagriSema: A Breakthrough in Obesity Treatment for Diabetics

Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...

Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now